Evidence map›Paper›PMID 34873595›Full record

ArticleResearch square2021

Tracking SARS-COV-2 Variants Using Nanopore Sequencing in Ukraine in Summer 2021.

Anna Yakovleva, Ganna Kovalenko, Matthew Redlinger, Mariia G Liulchuk, Eric Bortz, Viktoria I Zadorozhna, Alla M Scherbinska, Joel O Wertheim, Ian Goodfellow, Luke Meredith and 1 more

Abstract readPreprint
In one paragraph

Article in Research square, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Anna YakovlevaUniversity of Oxford.
Ganna KovalenkoUniversity of Cambridge.
Matthew RedlingerUniversity of Alaska Anchorage.
Mariia G LiulchukState Institution "L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of National Academy of Medical Sciences of Ukraine".
Eric BortzUniversity of Alaska Anchorage.
Viktoria I ZadorozhnaState Institution "L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of National Academy of Medical Sciences of Ukraine".
Alla M ScherbinskaState Institution "L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of National Academy of Medical Sciences of Ukraine".
Joel O WertheimUniversity of California San Diego.
Ian GoodfellowUniversity of Cambridge.
Luke MeredithUniversity of Cambridge.
Tetyana I VasylyevaUniversity of California San Diego.

Funding

The Administrative CoreP20GM103395 · NIGMS · UNIVERSITY OF ALASKA FAIRBANKS · PI BRIAN M BARNES · 2012 to 2026
$66.1M
Automation and Evaluation of Real-Time Transmission Network-Based HIV Prevention Services in New York CityR01AI135992 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WERTHEIM, JOEL OKRENT · 2018 to 2022
$3.6M
NIAID NIH HHS R01 AI135992NIGMS NIH HHS P20 GM103395Wellcome Trust
6 · The paper itself

Abstract

Since spring 2020, Ukraine has experienced at least two COVID-19 waves and has just entered a third wave in autumn 2021. The use of real-time genomic epidemiology has enabled the tracking of SARS-CoV-2 circulation patterns worldwide, thus informing evidence-based public health decision making, including implementation of travel restrictions and vaccine rollout strategies. However, insufficient capacity for local genetic sequencing in Ukraine and other Lower and Middle-Income countries limit opportunities for similar analyses. Herein, we report local sequencing of 24 SARS-CoV-2 genomes from patient samples collected in Kyiv in July 2021 using Oxford Nanopore MinION technology. Together with other published Ukrainian SARS-COV-2 genomes sequenced mostly abroad, our data suggest that the second wave of the epidemic in Ukraine (February-April 2021) was dominated by the Alpha variant of concern (VOC), while the beginning of the third wave has been dominated by the Delta VOC. Furthermore, our phylogeographic analysis revealed that the Delta variant was introduced into Ukraine in summer 2021 from multiple locations worldwide, with most introductions coming from Central and Eastern European countries. This study highlights the need to urgently integrate affordable and easily-scaled pathogen sequencing technologies in locations with less developed genomic infrastructure, in order to support local public health decision making.

Identifiers

PMID34873595
PMCPMC8647652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.